Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 10, 2017. The document serves as a transaction notification regarding dealings by a Person Discharging Managerial Responsibilities (PDMR) and does not contain general business updates or operational reports.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific securities transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Exercise of share options followed by an immediate sale.
- Volume: 4,820 shares.
- Exercise Price: £14.88 per share.
- Sale Price: £15.7590 per share.
- Transaction Date: February 9, 2017.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses a routine insider transaction involving the Company Secretary.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, contingencies, or unusual items. The document is a statutory disclosure of a specific share transaction.
Investor Verification Checklist
- Verify the identity of the PDMR: Mrs. V A Whyte (Company Secretary).
- Confirm the transaction date: February 9, 2017.
- Validate the share count: 4,820 ordinary shares.
- Check the pricing spread: Options exercised at £14.88 and sold at £15.7590.
- Confirm the source of the options: Granted on February 20, 2007, under the GlaxoSmithKline Share Option Plan.